Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIPISAFE: Optimal nivolumab + ipilimumab schedule in dMMR/MSI metastatic colorectal cancer
2020-004366-19Phase 2Active
- Sponsor
- GERCOR
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in colorectal adenocarcinoma (2 arms), sponsored by GERCOR. Primary endpoint: Grade 3 or 4 adverse events during first 24 weeks. Started Oct 2020; status: active.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on 2020-004366-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004366-19.